# DESCRIPTION

## FIELD OF THE INVENTION

- relate to chimeric antigen receptors

## BACKGROUND OF THE INVENTION

- motivate CAR-Tregs

## SUMMARY OF THE INVENTION

- identify limitations of CAR-Tregs
- introduce CD137 CAR solution

## DETAILED DESCRIPTION OF THE INVENTION

- define CAR structure
- describe CAR binding to antigen
- outline composition of Treg cells expressing CAR
- describe method for enrichment of activated Treg cells
- outline method for analyzing activation efficiency of Treg cells
- describe use of CD137 CAR to select optimal CARs
- summarize pharmaceutical compositions and methods of treatment
- define CAR domains
- motivate Treg activation
- describe Treg activation markers
- outline method for comparing CARs
- detail genetic modification of Treg cells
- describe method for analyzing antigen samples
- outline process for generating engineered Treg cells
- describe formulation and administration of engineered Treg cells
- discuss dosage and treatment of disorders

### Definitions

- define CAR structure
- describe antigen binding domain
- explain spacer/hinge region
- define transmembrane domain
- describe cytoplasmic signaling domain
- explain co-stimulatory signaling region
- define antibody and antibody fragments
- describe antigen and soluble antigen
- define key terms
- describe cell types and states
- explain immunotherapy and cell engineering
- define sequences and variants
- describe circulatory system and automated methods
- explain particle and cell sorting technologies

### EMBODIMENTS

- generate Treg expressing CAR with CD3zeta and CD137 signaling domains
- isolate and enrich Tregs from various sources
- expand and activate engineered Tregs with exogenous antigen

## Methods

### CAR Constructs

- generate CAR constructs

### Treg Isolation and Transduction

- isolate and transduce Tregs

### Flow Cytometry

- analyze cell surface expression

### Quantification of Gene Expression

- quantify gene expression by qRT-PCR

